PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
15-Mar-2022 ProteoGenix Launches New XtenCHO Transient CHO Expression System to Improve Biologics Development Sciad Newswire
15-Mar-2022 PharmaSGP achieves record results in 2021 - Adjusted EBITDA in Q4 up fivefold year-on-year PharmaSGP Holding SE
15-Mar-2022 APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052 APONTIS PHARMA AG
15-Mar-2022 Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU Relief Therapeutics Holding SA
15-Mar-2022 PolyPeptide achieves strong profitable growth in 2021 PolyPeptide Group
15-Mar-2022 Newron announces 2021 financial results and provides outlook for 2022 Newron Pharmaceuticals S.p.A.
14-Mar-2022 VERAXA Biotech GmbH Appoints Dr. Lars Hufnagel to Chief Technical Officer B3C newswire
11-Mar-2022 UCB Completes Acquisition of Zogenix, Inc. UCB
11-Mar-2022 Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis Tiziana Life Sciences
11-Mar-2022 Envirotainer and Swiss WorldCargo complete the first commercial shipment using the new Releye® RAP Envirotainer
11-Mar-2022 Grifols’ XEMBIFY® receives European approvals, expanding access to innovative therapies Grifols
11-Mar-2022 Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing Santhera Pharmaceuticals
11-Mar-2022 GARDP welcomes positive results in Venatorx phase 3 clinical trial of new treatment for serious bacterial infections GARDP
11-Mar-2022 US FDA clears Terumo Blood and Cell Technologies' new plasma collection technology Terumo Blood and Cell Technologies
11-Mar-2022 SYNLAB AG: SYNLAB joins the United Nations Global Compact initiative SYNLAB AG
11-Mar-2022 Medacta Group SA delivers 21.4% revenue growth in 2021 and strong adjusted EBITDA margin at 29.5% Medacta Group SA
10-Mar-2022 Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022 MorphoSys AG
10-Mar-2022 AEVIS VICTORIA SA sells its participation in Medgate to Otto Group AEVIS VICTORIA SA
10-Mar-2022 Ad hoc: MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021 MorphoSys AG
10-Mar-2022 Immutep receives constructive feedback from US FDA on its clinical development program for efti in metastatic breast cancer Immutep Limited